ValiRx plc Annual Report and Accounts 2017 ValiRx Plc (AIM: VAL), a life science company, which 
focuses on clinical stage cancer therapeutic development, 
The Company continues with the development of VAL301, 
Financial Statements ValiRx plc Annual Report and Accounts 2017 12
results, VAL201’s Phase I/II prostate cancer clinical 
Therapeutics, a Cancer Research UK company, 
Financial Statements ValiRx plc Annual Report and Accounts 2017 20
The Directors present their report and financial statements for the year ended 31 December 2017.
the year the Group expensed to the income statement £1,746,808 (2016: £2,375,354) on research and development.
The market value of the Company’s shares at 31 December 2017 was 4.38p and the high and low share prices during the period were 7.63p and  
Note 29 to the financial statements gives details of the Group’s objectives and policies for risk management of financial instruments.
The Directors are responsible for preparing the Annual Report and the Group and Parent Company financial statements in accordance with applicable  
Company law requires the Directors to prepare Group and parent financial statements for each financial year.
Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs 
Group and Parent Company financial statements the Directors are required to:
• for the Parent Company financial statements, state whether they have been prepared in accordance with applicable UK Accounting Standards, subject  
• prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group and the Parent Company will continue  
We have audited the financial statements of Valirx Plc (the ’Parent Company’) and its subsidiaries (the ’Group’) for the year ended 31 December 2017 on pages 26 to 54.
• the financial statements give a true and fair view of the state of the Group’s and of the Parent Company’s affairs as at 31 December 2017 and of the Group’s loss for 
• the Parent Company financial statements have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice –  
• the financial statements have been prepared in accordance with the requirements of the Companies Act 2006.
Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and 
We draw your attention to note 2 to the financial statements, which indicates that the company is reliant on future fund raisings to continue its activities as budgeted.
Should future fund raisings be unsuccessful this will impact to the group and company’s plans to develop its products.
The company granted warrants during the year to shareholders on a placing of ordinary shares and for services provided resulting in a charge of £158,765,  
We considered the charge provided in the financial statements of the group and company to be reasonable.
Materiality for the group and company was £115,000 (2016: £152,000) based on an average of 5% of adjusted loss before tax and 1% of net assets (2016: based on 5% 
• the information given in the Group Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared  
• the Parent Company financial statements are not in agreement with the accounting records and returns; or 
In preparing the financial statements, the directors are responsible for assessing the group’s and the parent company’s ability to continue as  a going concern, 
COMPANY STATEMENT OF FINANCIAL POSITION
the nominal value of the share capital issued by the Company and the fair value of ValiRx Bioinnovation at 3 October 2006, the date of acquisition.
Represents the difference between the nominal value of the share capital issued by the Company and the fair value of ValiRx Bioinnovations at the date  
The Group financial statements have been prepared under the historical cost convention or fair value where appropriate.
The Board expects to continue to raise additional funding as and when required to cover the Group’s development, primarily from the issue of further shares.
Although the Directors have a reasonable expectation that the Company and the Group have adequate resources to continue in operational existence for 
The Group financial statements consolidate the financial statements of the Company and all its subsidiaries (“the Group”).
Goodwill on acquisition of subsidiaries represents the excess of the cost of acquisition over the fair value of the Group’s share of the identifiable net assets 
• financial assets at fair value through profit or loss;
The Group does not have any financial liabilities that would be classified as fair value through the profit or loss.
IFRS 2 “Share-based Payments” requires that an expense for equity instruments granted is recognised in the financial statements based on their fair values 
early by the Company as they are not expected to have a material impact on the financial statements other than requiring additional disclosure or alternative 
assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period.
The Parent Company’s loss for the financial year was £2,679,773 (2016: £4,615,202).
The Company’s investments at the Statement of Financial Position date in the share capital of companies include the following: 
The fair value of the derivative financial assets has been determined by reference to the Company’s share price and has been estimated as follows:
In March 2017, certain directors of the Company subscribed £30,000 through the issue of 1,200,000 new ordinary shares at a price of 2.5 pence per share.
In September 2017, the Company raised £0.5 million, before expenses, through the issue of 50,000,000 new ordinary shares at a price of 1p per share.
In December 2017, the Company received notifications of the exercise of warrants over 3,000,000 ordinary shares at an exercise price of 1p and over 
During the year the Director O de Giorgio – Miller invoiced the Company £49,500 (2016: £64,609) for research and development work.